Delivery Order SPE2DB22D1017-SPE2DB25FG8SB
- Not listed
- The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $4,512.00 delivery order on July 21, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price contract with a completion date of July 22, 2025, and represents a non-set-aside competitive award. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Myrbetriq ER 25 mg tablets (90-count supply) with a contract ceiling value of $7,101.28. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- AmerisourceBergen Drug Corp has been awarded a delivery order from the Defense Logistics Agency for $12,459.55 to supply Myrbetriq ER 50 mg tablets in a 90-count quantity. The award was issued on July 30, 2025, with an ultimate completion date of July 31, 2025, and utilizes firm fixed pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order represents a competitive...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,248.63 by the Defense Logistics Agency on July 25, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count packaging). The contract employs firm fixed pricing and carries an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate office and primary distribution hub...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.94 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, this firm fixed-price contract utilized competitive procedures with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $36,113.23 on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by July 30, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract valued at $8,276.16. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8SBDelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $28,170.24 by the Defense Logistics Agency (DLA) for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp regularly supplies the Department of Defense and military healthcare systems with a broad portfolio of brand-name and generic medications, vaccines, and medical supplies. This delivery order for Myrbetriq, a medication used in the treatment of overactive bladder, exemplifies the company's role in supporting the Defense Health Agency's pharmaceutical supply chain. The competitively awarded nature of this transaction and the company's significant prime vendor status with DLA demonstrate AmerisourceBergen's capability to meet federal medical procurement requirements across multiple therapeutic domains and scales of delivery.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.2k | 7/31/25 |